FTC's Health Care Reform Plan: Save $12 Billion With Reverse Settlement Ban
Executive Summary
The Federal Trade Commission has drawn another arrow in its attempt to shoot down reverse settlements between brand and generic drug companies - offering an estimate of $12 billion in government savings over the next 10 years from ending the practice